ライフサイエンスコーパス: patient health questionnaire

1 chological assessments, based on the PHQ-15 (Patient Health Questionnaire).

2 rder scale), and problem drinking (using the Patient Health Questionnaire).

3 pression symptoms (measured using the 9-item Patient Health Questionnaire).

4 erformance Battery) and depressive symptoms (Patient Health Questionnaire).

5 impairment, and depressive symptoms (2-item Patient Health Questionnaire).

6 and symptoms of depressive disorder (9-item Patient Health Questionnaire).

7 Major depression was assessed with the Patient Health Questionnaire.

8 Checklist; depression was assessed with the Patient Health Questionnaire.

9 essive and anxiety symptoms assessed via the Patient Health Questionnaire.

10 ental distress was measured using the 4-item Patient Health Questionnaire.

11 of 10 or more for the 8-item version of the Patient Health Questionnaire.

12 epressive symptoms as measured by the 9-item Patient Health Questionnaire.

13 nxiety Disorder 7-item scale, and the 8-item Patient Health Questionnaire.

14 d 10 or more on the locally validated 9-item Patient Health Questionnaire.

15 ere screened for depression using the 9-item Patient Health Questionnaire.

16 atic stress symptoms were assessed using the Patient Health Questionnaire-13 (PHQ-13) and Child PTSD

17 The primary outcome was Patient Health Questionnaire-15 (PHQ-15) score 52 weeks

18 nal neurological symptoms as measured by the Patient Health Questionnaire-15 and the Screening for So

19 rm Symptoms Conversion Disorder subscale and Patient Health Questionnaire-15 composite score.

20 y and Depression Scale questionnaire and the Patient Health Questionnaire-15.

21 ded the number of patients screened with the patient health questionnaire 2 (PHQ-2), cases of remitte

22 The UK Biobank recorded the 2-item Patient Health Questionnaire 2 (PHQ-2; range, 0-6; >=3 i

23 The Primary Care PTSD Screen, the Patient Health Questionnaire-2 (modified), the suicidal

24 The Patient Health Questionnaire-2 (PHQ-2) consists of the f

25 screen for positive Coping Screen patients (Patient Health Questionnaire-2 [PHQ-2], GAD-2, and an it

26 ized Anxiety Disorder 2-item for anxiety and Patient Health Questionnaire-2 for depression).

27 mplate comprising five questions (a two-item Patient Health Questionnaire-2 for depression, a two-ite

28 to be present if patients had a score on the Patient Health Questionnaire-2 of 3 or higher (the tool

29 comes included depression (measured with the Patient Health Questionnaire-2 scale) and anxiety (measu

30 ; P=0.96) or the proportion of patients with Patient Health Questionnaire-2 score >=3 (15.1% versus 1

31 up (150 participants; difference in means of Patient Health Questionnaire-2, 0.8 [95% CI, 0.2 to 1.3]

32 onflict Scale, depressive symptoms using the Patient Health Questionnaire-2, and stress using the Per

33 Questionnaire (DCQ), Perceived Stress Scale, Patient Health Questionnaire-2, General Anxiety Disorder

34 s for KCCQ-CSS and 2624 (91.8%) patients for Patient Health Questionnaire-2.

35 Depressive symptom was assessed by the Patient Health Questionnaire-2.

36 ng performed by medical assistants using the Patient Health Questionnaire-2.

37 nd depression symptoms were measured via the Patient Health Questionnaire-4 ([PHQ-4]; range, 0-12; sc

38 ptom Assessment System (ESAS) and the 4-item Patient Health Questionnaire-4 (PHQ-4) daily via tablet

39 System [ESAS]), and psychological symptoms (Patient Health Questionnaire-4 [PHQ4] total, PHQ4-depres

40 5% CI, 1.003 to 1.032; P < .017), and higher Patient Health Questionnaire-4 depression symptoms (OR,

41 ealthy Days Core Module-4, Short Form-36 and Patient Health Questionnaire-4) and two newly developed

42 sessment System) and psychological distress (Patient Health Questionnaire-4).

43 their depressive symptom scores through the Patient Health Questionnaire-4.

44 The Patient Health Questionnaire 8, International Classifica

45 er-6 (K6)) and depressive symptoms using the Patient Health Questionnaire-8 (PHQ8), with higher score

46 Depression symptoms were evaluated by the Patient Health Questionnaire-8 and anxiety symptoms were

47 training but were not hired) who completed a Patient Health Questionnaire-8 and four-item Primary Car

48 Primary outcomes were depression (Patient Health Questionnaire-8 item) and anxiety (Genera

49 te to severe symptoms of current depression (Patient Health Questionnaire-8 score >=10) and anxiety (

50 ardiomyopathy Questionnaire-12), depression (Patient Health Questionnaire-8) and anxiety (Generalized

51 -Life Dementia scores, caregiver depression (Patient Health Questionnaire-8) scores, caregiver distre

52 health status (EQ-5D), depressive symptoms (Patient Health Questionnaire-8), and, for North American

53 generalized anxiety disorder-7), depression (patient health questionnaire-8), PTSD (8Q-PCL-5), pain,

54 rformance Battery), and depressive symptoms (Patient Health Questionnaire-8).

55 m Health Survey, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and the EQ-5D.

56 Quality of Life; r=-0.581, P<0.001 with the Patient Health Questionnaire-8; and r=-0.540, P<0.001 wi

57 aged 18-65 years scoring more than 14 on the Patient Health Questionnaire 9 (PHQ-9) indicating modera

58 ion used; stratified by depression severity [Patient Health Questionnaire 9 (PHQ-9) score of <19 vs >

59 to have access to the internet and email, a Patient Health Questionnaire 9 (PHQ-9) score of at least

60 oderately severe to severe depression on the Patient Health Questionnaire 9 (PHQ-9) were randomised t

61 iable was a depression score measured by the Patient Health Questionnaire 9 (PHQ-9), a self-report qu

62 omnia and hypersomnia]) as measured with the Patient Health Questionnaire 9 (up to 117 907 individual

63 on literature review: depression screening (Patient Health Questionnaire 9 [PHQ-9]), social support

64 Nonquitters worsened slightly on the Patient Health Questionnaire 9 relative to quitters (dif

65 prescription, and utilization variables and Patient Health Questionnaire 9 responses.

66 r and at least moderate depression severity (Patient Health Questionnaire 9 score > or = 10).

67 was no evidence of an intervention effect on Patient Health Questionnaire 9 score, suicidal behaviour

68 etes Mellitus, Diabetes Self-Care Inventory, Patient Health Questionnaire 9, and National Eye Institu

69 4-item Hamilton Rating Scale for Depression, Patient Health Questionnaire 9, and the Center for Epide

70 atedly assessed using the PTSD Checklist and Patient Health Questionnaire 9, respectively, to determi

71 h outcomes of interest were assessed via the Patient Health Questionnaire 9-item (PHQ-9) and Generali

72 depressive symptoms were measured using the Patient Health Questionnaire 9-item (PHQ-9).

73 years) who screened positive for depression (Patient Health Questionnaire 9-item [PHQ-9] score >/=10)

74 n or anxiety assessed in July 2021 using the Patient Health Questionnaire 9-item and Generalized Anxi

75 the Veterans RAND 12-Item Health Survey, the Patient Health Questionnaire 9-item depression scale (PH

76 ception Questionnaire), depression severity (Patient Health Questionnaire 9-item depression scale), a

77 ess Disorder Checklist-Civilian Version, the Patient Health Questionnaire 9-item depression scale, an

78 ess (depression and anxiety; measured by the Patient Health Questionnaire 9-item scale and the Genera

79 y Assessment of Psychic Experiences 15-item, Patient Health Questionnaire 9-item, and Generalized Anx

80 the Hospital Anxiety and Depression Scale or Patient Health Questionnaire 9-Item, Generalized Anxiety

81 oms 6 weeks after randomisation, measured by Patient Health Questionnaire, 9-item version (PHQ-9) sco

82 reported their depression symptoms using the Patient Health Questionnaire-9 (cutoff scores for modera

83 essed using self-rating instruments like the Patient Health Questionnaire-9 (PHQ-9) (current symptoms

84 on of depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) (remission was de

85 depressive symptoms were measured using the Patient Health Questionnaire-9 (PHQ-9) and categorized u

86 e and anxiety symptoms were assessed via the Patient Health Questionnaire-9 (PHQ-9) and Generalized A

87 ssessed at baseline and at 12 weeks with the Patient Health Questionnaire-9 (PHQ-9) and was scored di

88 f Louisville who scored 10 or greater on the Patient Health Questionnaire-9 (PHQ-9) and were randomly

89 cularly the anxiety dimension and the use of Patient Health Questionnaire-9 (PHQ-9) as depression sev

90 ve symptoms from baseline as assessed by the Patient Health Questionnaire-9 (PHQ-9) depression scale

91 in studies of the diagnostic accuracy of the Patient Health Questionnaire-9 (PHQ-9) depression screen

92 The Patient Health Questionnaire-9 (PHQ-9) depressive sympto

93 Research coordinators administered the Patient Health Questionnaire-9 (PHQ-9) during the index

94 n, dexterity, emotion, cognition, and pain), Patient Health Questionnaire-9 (PHQ-9) for depression, a

95 years or older who scored at least 10 on the Patient Health Questionnaire-9 (PHQ-9) from antenatal cl

96 dults aged 18 to 50 years whose score on the Patient Health Questionnaire-9 (PHQ-9) indicated moderat

97 Prevalent depression was defined as having a Patient Health Questionnaire-9 (PHQ-9) score of >=10.

98 erate, or severe depression as calculated by Patient Health Questionnaire-9 (PHQ-9) scores (P < 0.001

99 depression symptoms defined by self-reported Patient Health Questionnaire-9 (PHQ-9) scores of 10 or g

100 ys to screen for depression using the 9-item Patient Health Questionnaire-9 (PHQ-9) throughout and af

101 Secondary outcomes included the Patient Health Questionnaire-9 (PHQ-9) to assess depress

102 ed (i) the relationships between depression (Patient Health Questionnaire-9 (PHQ-9)), SRDA (IBD-Contr

103 ttraumatic stress disorder symptoms; (3) the Patient Health Questionnaire-9 (PHQ-9), a 9-item scale t

104 Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), and all-cause mo

105 using the two single-item burnout measures, Patient Health Questionnaire-9 (PHQ-9), and Generalized

106 the Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Primary Care

107 e Oldenburg Burnout Inventory (OLBI) and the Patient Health Questionnaire-9 (PHQ-9), and provided dem

108 uded the following validated questionnaires: Patient Health Questionnaire-9 (PHQ-9), Generalized Anxi

109 The Patient Health Questionnaire-9 (PHQ-9), Generalized Anxi

110 mental health functioning determined via the Patient Health Questionnaire-9 (PHQ-9), the Generalised

111 Patients completed the Patient Health Questionnaire-9 (PHQ-9), which included I

112 s or older who had scored at least 10 on the Patient Health Questionnaire-9 (PHQ-9), who we recruited

113 ssion, as determined by a score >/=10 on the Patient Health Questionnaire-9 (PHQ-9).

114 Ham-D) and self-reported depression with the Patient Health Questionnaire-9 (PHQ-9).

115 on was assessed by the Korean version of the Patient Health Questionnaire-9 (PHQ-9).

116 Depression was assessed with the Patient Health Questionnaire-9 (PHQ-9).

117 Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9); county-level com

118 versal screening, all students completed the Patient Health Questionnaire-9 (PHQ-9); students with po

119 e (FOSQ), Insomnia Severity Index (ISI), and Patient Health Questionnaire-9 (PHQ-9; depression) score

120 ge in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9; score range: 0-27

121 rental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scor

122 least moderate symptoms of depression on the Patient Health Questionnaire-9 (score >=10) were enrolle

123 IMPROVE-2) recruited adults with depression (Patient Health Questionnaire-9 [PHQ-9] score >=10) from

124 clinically significant depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] score >=10).

125 clinically significant depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] score 10) who wer

126 322 patients without depression, defined by Patient Health Questionnaire-9 [PHQ-9] score) conducted

127 x, 25-40) with elevated depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] scores >=5) and n

128 pressive symptom severity (measured with the Patient Health Questionnaire-9 [PHQ-9]), current depress

129 Symptom Inventory-18 [BSI-18]), depressive (Patient Health Questionnaire-9 [PHQ-9]), posttraumatic s

130 derate to severe depression according to the Patient Health Questionnaire-9 [RR, 2.3; 95% CI, 1.5 to

131 ores improved significantly in all arms, and Patient Health Questionnaire-9 and Functional Assessment

132 ED was assessed by Patient Health Questionnaire-9 and Generalized Anxiety D

133 rom the state Prescription Drug Program; and Patient Health Questionnaire-9 and PTSD Checklist for DS

134 or of the experimental condition only on the Patient Health Questionnaire-9 and quality of life.

135 The Patient Health Questionnaire-9 and rumination scales (TG

136 ss disorder symptoms were assessed using the Patient Health Questionnaire-9 and the Posttraumatic Str

137 Depressive symptoms were assessed with Patient Health Questionnaire-9 at baseline and during fi

138 iagnostic criteria for insomnia disorder and Patient Health Questionnaire-9 criteria (score >=10) for

139 ta Elements (ie, Brief Symptom Inventory-18, Patient Health Questionnaire-9 Depression checklist, Pos

140 The Patient Health Questionnaire-9 depression screener showe

141 sing a combination of questions based on the Patient Health Questionnaire-9 depression screening ques

142 The Patient Health Questionnaire-9 detected moderate to seve

143 Primary outcomes were the Patient Health Questionnaire-9 for depression (range, 0-

144 ons Questionnaire for work outcomes, and the Patient Health Questionnaire-9 for depression.

145 odologically, these models indicate that the Patient Health Questionnaire-9 is scalar noninvariant as

146 tient-reported depressive symptoms using the Patient Health Questionnaire-9 item (PHQ-9) at treatment

147 depression or self-harm defined by either a Patient Health Questionnaire-9 item (PHQ-9) score of 10

148 ing Scale [EES]) and psychological distress (Patient Health Questionnaire-9 item scale [PHQ-9] and Ge

149 ve symptoms" defined as a composite score of Patient Health Questionnaire-9 items related to sleep di

150 ebruary 2022 through May 2023, including the Patient Health Questionnaire-9 Modified for Teens (PHQ-9

151 The participating patients had depression (Patient Health Questionnaire-9 score > or = 10), cancer-

152 ms and probable major depression (defined as Patient Health Questionnaire-9 score >/=10).

153 patients with elevated depressive symptoms (Patient Health Questionnaire-9 score >=10) and/or SI, ex

154 and diabetes care with signs of depression (Patient Health Questionnaire-9 score >=5).

155 ressive symptoms assessed from self-reported Patient Health Questionnaire-9 score at 13 years (n = 57

156 ssion severity (difference in mean change in Patient Health Questionnaire-9 score from baseline, -2.9

157 osis of MDD and current depressive symptoms (Patient Health Questionnaire-9 score of 5 or more).

158 t recruited patients with type 2 diabetes; a Patient Health Questionnaire-9 score of at least 10 (ran

159 The mean (SD) Patient Health Questionnaire-9 score was significantly h

160 argets; and mean reductions in SCL-20 score, Patient Health Questionnaire-9 score, HbA1c, SBP, and LD

161 ine; -1.0 (95% CI, -2.3 to 0.3; P = .13) for Patient Health Questionnaire-9 score; and -0.9 (95% CI,

162 Depressive symptoms were defined by Patient Health Questionnaire-9 scores and were categoriz

163 ariant as a function of CRP (i.e., identical Patient Health Questionnaire-9 scores may represent diff

164 were stratified by AD symptom severity using Patient Health Questionnaire-9 scores.

165 ive-related symptoms were measured using the Patient Health Questionnaire-9 scoring system.

166 The Patient Health Questionnaire-9 was used to assess depres

167 The Patient Health Questionnaire-9 was used to assess suicid

168 ened positive (a score of at least 10 on the Patient Health Questionnaire-9) and met criteria for maj

169 ancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), and coping (Brief COPE)

170 Food security status, depression symptoms (Patient Health Questionnaire-9), and quality-of-life sco

171 ere detox changes in symptoms of depression (Patient Health Questionnaire-9), anxiety (Generalized An

172 Secondary outcomes included depression (Patient Health Questionnaire-9), somatic symptoms (Somat

173 cellent), and depression (measured using the Patient Health Questionnaire-9).

174 ine to week 24, change in depression per the Patient Health Questionnaire-9, and differences in end-o

175 nges in the PTSD Checklist for DSM-5 and the Patient Health Questionnaire-9, and proportion of respon

176 ed), the suicidal ideation question from the Patient Health Questionnaire-9, and several other questi

177 S, the Hamilton Depression Rating Scale, the Patient Health Questionnaire-9, and the Quality of Life

178 es were the PTSD Checklist-Civilian Version, Patient Health Questionnaire-9, Generalised Anxiety Diso

179 major depressive disorder as measured by the Patient Health Questionnaire-9, health care utilization

180 e-15, Hospital Anxiety and Depression Scale, Patient Health Questionnaire-9, Profile of Mood States-S

181 ralized Anxiety Disorder-7 questionnaire and Patient Health Questionnaire-9, respectively, with ulcer

182 neralized Anxiety Disorder 7-item scale, the Patient Health Questionnaire-9, the Perceived Stress Sca

183 Anxiety and Depression Scale (HADS) and the Patient Health Questionnaire-9, which also assessed suic

184 the neonatal period were measured using the Patient Health Questionnaire-9, with a score of 10 or hi

185 improvement in depression as measured by the Patient Health Questionnaire-9.

186 Depression was assessed using the Patient Health Questionnaire-9.

187 y of cognitive symptoms in the past week and patient Health Questionnaire-9.

188 Diagnosis of major depression based on the Patient Health Questionnaire-9.

189 ts in United States and Canada completed the Patient Health Questionnaire-9.

190 ty Disorder-7 and depression measured by the Patient Health Questionnaire-9.

191 : 29 +/- 25 vs. 10 +/- 22 [p < 0.001]; Delta Patient Health Questionnaire-9: -5 +/- 7 vs. -1 +/- 5 [p

192 symptom report of depression before surgery (Patient Health Questionnaire-9: OR, 1.3; 95% CI, 1.1-1.6

193 igue), psychiatric (Insomnia Severity Scale; Patient Health Questionnaire-9; and Posttraumatic Stress

194 Disorders; depression was assessed with the Patient Health Questionnaire-9; anxiety was assessed wit

195 he Hospital Anxiety and Depression Scale and Patient Health Questionnaire (adjusted mean difference,

196 sive mood and distress symptoms based on the Patient Health Questionnaire and distress thermometer we

197 ere assessed using shortened versions of the Patient Health Questionnaire and Generalized Anxiety Dis

198 Primary Care Evaluation of Mental Disorders Patient Health Questionnaire and modified CAGE questionn

199 xiety, depression, and somatic scores on the Patient Health Questionnaire and Posttraumatic Stress Di

200 sed using shortened (2-item) versions of the Patient Health Questionnaire and the Generalized Anxiety

201 epression and anxiety were assessed with the Patient Health Questionnaire and the Generalized Anxiety

202 ompleted 2 questionnaires, the PHQ-9 (9-item Patient Health Questionnaire) and the CarCGQoL (Caregive

203 short form), depression (score on the 8-item Patient Health Questionnaire), and fatigue (score on the

204 L]), anxiety and depression (measured by the Patient Health Questionnaire), and grip strength.

205 xiety Subscale), depressive symptoms (9-item Patient Health Questionnaire), and social support (20-it

206 l depressive symptoms were assessed with the Patient Health Questionnaire, and data on harsh child di

207 2-item Generalized Anxiety Disorder, 2-item Patient Health Questionnaire, and UCLA Loneliness Scale-

208 self-reported depression (measured using the Patient Health Questionnaire), anxiety (measured using t

209 ted to a score of 6 or greater on the 4-item Patient Health Questionnaire (area under the receiver op

210 reened positive for depression on the 2-item Patient Health Questionnaire at 82 primary care VA clini

211 d adequate test accuracy (eg, for the 9-item Patient Health Questionnaire at a cutoff of 10 or greate

212 f standard care administration of the 9-item Patient Health Questionnaire between sexual minority wom

213 -5D-5L) (0.06 [95% CI, 0.01-0.11]; P = .02), Patient Health Questionnaire category (0.5 [95% CI, 0.2-

214 The Patient Health Questionnaire depression module (PHQ-9) i

215 thers were examined for depression using the Patient Health Questionnaire depression module antepartu

216 or further analysis, focus was placed on the Patient Health Questionnaire Depression Scale (PHQ-8), t

217 d the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; s

218 t suicidal thoughts identified using routine Patient Health Questionnaire depression screening at 4 U

219 Published studies utilizing the nine-item Patient Health Questionnaire did not show evidence of wo

220 gh Postnatal Depression Scale and the 9-item Patient Health Questionnaire; elevated depression sympto

221 December 2010 and completed a 1-time 9-item Patient Health Questionnaire for depression categorized

222 ening instruments, the GAD-7 for GAD and the Patient Health Questionnaire for panic disorder, have go

223 naire exhibited convergent validity with the Patient Health Questionnaire for symptoms of depression

224 nd somatic physical symptoms portions of the Patient Health Questionnaires for Adolescents (PHQ-15A),

225 PCL-5), major depressive disorder (using the Patient Health Questionnaire), generalized anxiety (usin

226 ymptoms, defined as an elevated score on the Patient Health Questionnaire (>/= 10) and/or a diagnosis

227 with scores indicative of depression (9-item Patient Health Questionnaire, >/=10) showed greater cogn

228 Data were sparse for Patient Health Questionnaire instruments.

229 surveys measuring (1) depression through the Patient Health Questionnaire-ninth version, (2) anxiety

230 ssive symptoms were measured with the 8-item Patient Health Questionnaire, perceived stress with the

231 y used self-rated symptom questionnaire- the Patient Health Questionnaire (PHQ 15) (plus enhanced ite

232 ith 23 cross-sectional networks based on the Patient Health Questionnaire (PHQ) and Generalized Anxie

233 The Patient Health Questionnaire (PHQ) depression and anxiet

234 rity Index for alcohol and drug outcomes and Patient Health Questionnaire (PHQ) for depression).

235 Screening for depression using the Patient Health Questionnaire (PHQ) has been extensively

236 Given that the Patient Health Questionnaire (PHQ) item 9 is commonly us

237 ressant medication, or screened positive via Patient Health Questionnaire (PHQ)-2 or PHQ-9.

238 e 3, depressive symptoms were assessed using Patient Health Questionnaire (PHQ)-8 in a general Europe

239 Depressive symptoms were assessed with the Patient Health Questionnaire (PHQ)-9 (continuous score,

240 ecificity:0.83; 95% CI 0.72 to 0.90) and the Patient Health Questionnaire (PHQ)-9 (sensitivity: 0.86;

241 depressive symptoms were assessed using the Patient Health Questionnaire (PHQ).

242 We investigated the potential of the 2-item patient health questionnaire (PHQ-2) versus that of the

243 were assessed with a modified version of the Patient Health Questionnaire (PHQ-4).

244 e (SSQ >=8) and depression measured with the Patient Health Questionnaire (PHQ-9 >=10) and health uti

245 1; Cohen d, 0.90; 90% CI, 0.63-1.19), 9-item Patient Health Questionnaire (PHQ-9) (slope [SE],-11.94

246 Depressive symptoms were assessed by the Patient Health Questionnaire (PHQ-9) and anxiety symptom

247 The Patient Health Questionnaire (PHQ-9) and Generalised Anx

248 vited to complete a survey that included the Patient Health Questionnaire (PHQ-9) and the 15-item Mut

249 pression and anxiety were assessed using the Patient Health Questionnaire (PHQ-9) and the Generalized

250 lic universities in Bangladesh completed the Patient Health Questionnaire (PHQ-9) scale, the Generali

251 with a 5 point or greater increase in 9-item Patient Health Questionnaire (PHQ-9) score as outcome an

252 The preregistered primary outcome was Patient Health Questionnaire (PHQ-9) score at 16 weeks p

253 Her nine-question Patient Health Questionnaire (PHQ-9) score is 17 (on a s

254 A 9-item Patient Health Questionnaire (PHQ-9) score of 9 or lower

255 ified with depressive symptomatology (9-item Patient Health Questionnaire (PHQ-9) scores >= 10) recei

256 e primary outcome was the difference in mean Patient Health Questionnaire (PHQ-9) scores at 3 months

257 years or older in central Uganda with 9-item Patient Health Questionnaire (PHQ-9) scores of 10 or gre

258 r greater (>=27 for Asian adults) and 9-item Patient Health Questionnaire (PHQ-9) scores of 10 or gre

259 Participants also completed the Patient Health Questionnaire (PHQ-9) to assess depressiv

260 Depression was defined by a Patient Health Questionnaire (PHQ-9) total score >=10.

261 y, the score for the depression scale of the Patient Health Questionnaire (PHQ-9) was significantly h

262 Patients who scored 9 or above on the Patient Health Questionnaire (PHQ-9) were administered t

263 sed for depressive symptoms using the 9-item Patient Health Questionnaire (PHQ-9), a series of psycho

264 therapists, scored 10 or more on the 9-item Patient Health Questionnaire (PHQ-9), and received a dia

265 (positive) screen assessed using the 9-item Patient Health Questionnaire (PHQ-9), and the Edinburgh

266 Neurologic Study-Lability Scale (CNS-LS) and Patient Health Questionnaire (PHQ-9), respectively) were

267 Everyday Discrimination Scale and the 9-item Patient Health Questionnaire (PHQ-9), respectively.

268 n the depressive symptom scale of the 9-item Patient Health Questionnaire (PHQ-9).

269 intervention to under 2 points on the 9-item Patient Health Questionnaire (PHQ-9).

270 n symptoms at 6 months, as measured with the Patient Health Questionnaire (PHQ-9).

271 men's depressive symptoms as measured by the Patient Health Questionnaire (PHQ-9).

272 severity at 4-month follow-up on the 9-item Patient Health Questionnaire (PHQ-9; score range, 0-27).

273 nd somatic physical symptoms portions of the Patient Health Questionnaires (PHQ-15), and the PTSD Che

274 ve symptoms was obtained using the validated Patient-Health Questionnaire (PHQ), scoring 10 or greate

275 ases); mean difference in mood score (8-item Patient Health Questionnaire [PHQ-8] depression scale).

276 >=10) and/or depression (defined as a 9-item Patient Health Questionnaire [PHQ-9] score of >=10).

277 measures of depressive symptoms (eg, 9-item Patient Health Questionnaire [PHQ-9]) are increasingly u

278 re depression (scoring >=11 on the nine-item patient health questionnaire [PHQ-9]).

279 service use, depression (measured using the Patient Health Questionnaire [PHQ]-9), and mental health

280 ety Related Disorders (SCAARED), depression (Patient Health Questionnaire [PHQ]-9), and somatic physi

281 isorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptan

282 he Hospital Anxiety and Depression Scale and Patient Health Questionnaire, PTSD checklist, and Functi

283 Depression, assessed using the 8-item Patient Health Questionnaire (range, 0-24, with higher s

284 0-21), depression (measured using the 9-item Patient Health Questionnaire scale [PHQ-9]; total score

285 1018 adults with depressive symptoms (8-item Patient Health Questionnaire score >/=10), 88% of whom w

286 index >30), and depressive symptoms (2-item Patient Health Questionnaire score >=2) per quarter-year

287 mated crude prevalence of depression (9-item Patient Health Questionnaire score of >/=10) was 11.3% (

288 g, and active symptoms of depression (9-item Patient Health Questionnaire score of 10 or more) at scr

289 depression categorized as: none to minimal (Patient Health Questionnaire score, 0-4), mild (5-9), or

290 logical Studies-Depression Scale, and 9-item Patient Health Questionnaire scores.

291 PHQ-9 (Patient Health Questionnaire) testing revealed 42% had m

292 d functioning were measured using the 9-Item Patient Health Questionnaire, the Altman Self-Rating Man

293 Feelings Questionnaire, the 8-item or 9-item Patient Health Questionnaire, the Hospital Anxiety and D

294 hological state was measured with the 9-item Patient Health Questionnaire, the PTSD Checklist-Militar

295 ical Arousal, Anger, and Numbness), Prime-MD Patient Health Questionnaire, TWEAK (Tolerance/Worry Abo

296 The 9-item Patient Health Questionnaire was used to assess depressi

297 Depressive symptoms (9-item Patient Health Questionnaire) were assessed during index

298 e estimates ranged from 20.9% for the 9-item Patient Health Questionnaire with a cutoff of 10 or more

299 t-performing test for panic disorder was the Patient Health Questionnaire, with a positive likelihood

300 measured as a binary variable via the 9-item Patient Health Questionnaire, with a range of 0 (best) t